Pick a medication, enter your weight and plan price, and see a projection built on the published flagship trials — semaglutide’s STEP 1 (~15% average loss over 68 weeks) and tirzepatide’s SURMOUNT-1 (up to ~21% at the highest dose over 72 weeks). A projection, not a promise. Nothing you enter leaves this page.
Based on trial averages, not a personal prediction — individual results vary widely, and dose titration means early months typically produce less change than the average suggests.
Start My Free VisitProjection math: trial-average total loss (semaglutide ~14.9% of body weight over 68 weeks, STEP 1; tirzepatide up to ~20.9% over 72 weeks at the highest dose, SURMOUNT-1) scaled linearly to your selected duration and capped at the trial timeline. Educational only — not medical or financial advice. Entries never leave your browser. Prescription treatment requires clinician evaluation; compounded medications are prepared by US-licensed pharmacies when prescribed and are not separately FDA-evaluated. Related reading: tirzepatide vs semaglutide and what compounded tirzepatide costs.